We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Health Agencies Update |

Sickle Cell Trial Halted

Bridget M. Kuehn
JAMA. 2010;304(4):398. doi:10.1001/jama.2010.968.
Text Size: A A A
Published online


A 26-site clinical trial in children with sickle cell anemia who had experienced a stroke that compares a new strategy to prevent a second stroke with the current standard of care has been ended early by the National Heart, Lung, and Blood Institute (NHLBI). It was halted because preliminary data suggested that the experimental therapy is unlikely to improve outcomes, according to a statement by the agency.

The Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) trial sought to determine if treatment with hydroxyurea and phlebotomy (to reduce excess iron) would help to prevent future strokes in children with sickle cell anemia who had already experienced one. Study sites had enrolled 133 patients aged 5 through 18 years and randomized them to either the experimental therapy or the standard of care (blood transfusions plus the iron-removal drug deferasirox). However, after the data and safety monitoring board found in an interim analysis that phlebotomy did not reduce liver iron better than deferasirox, it recommended halting the trial, and the NHLBI did so on May 6. Based on the data collected to that point, no strokes occurred in the 66 patients receiving blood transfusions and deferasirox; however, 7 strokes occurred among the 67 patients receiving hydroxyurea and phlebotomy.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles